Successful living donor liver transplantation with cavoportal hemitransposition in diffuse portomesenteric thrombosis
Manish Srivastava, Vinay Kumaran, Samiran Nundy, Naimish Mehta – 30 September 2014
Long‐term results of combined liver‐kidney transplantation for primary hyperoxaluria type 1: The French Experience
Philippe Compagnon, Philippe Metzler, Didier Samuel, Christophe Camus, Patrick Niaudet, Antoine Durrbach, Philippe Lang, Daniel Azoulay, Christophe Duvoux, Francois Bayle, Joseph Rivalan, Pierre Merville, Gerard Pascal, Eric Thervet, Albert Bensman, Lionel Rostaing, Georges Deschenes, Jeff Morcet, Cyrille Feray, Karim Boudjema – 30 September 2014 – Primary hyperoxaluria type 1 (PH1) is a hepatic metabolic defect leading to end‐stage renal failure. The posttransplant recurrence of kidney disease can suggest a need for combined liver‐kidney transplantation (LKT).
Use of nontraditional anticoagulants in portal vein thrombosis: A note of caution
Douglas A. Simonetto, Waldemar E. Wysokinski, Patrick S. Kamath – 29 September 2014
Mutant Ninja viruses
Graham R. Foster – 29 September 2014
Hepatitis A hospitalizations in the United States, 2002‐2011
Melissa G. Collier, Xin Tong, Fujie Xu – 29 September 2014
Management of portal vein thrombosis after liver transplantation with a combined open and endovascular approach
Clark D. Kensinger, Kevin W. Sexton, Christopher M. Baron, Andrew J. Lipnik, Steven G. Meranze, D. Lee Gorden – 29 September 2014
Long‐term outcome after liver transplantation for hepatic schistosomiasis: A single‐center experience over 15 years
Walid Moghazy, Samy Kashkoush, Wael O'hali, Khalid Abdallah – 29 September 2014 – Our objective was to study the long‐term outcomes of patients who had undergone liver transplantation because of schistosomiasis at our institute over the last 15 years. Four hundred forty‐one patients underwent liver transplantation at our institute, and 14 did so for schistosomiasis. The survival of patients who underwent transplantation for schistosomiasis was compared with that of patients who underwent transplantation for other liver diseases.
Reply
Melissa Martinez, Anand Tandra, Raj Vuppalanchi – 29 September 2014
Dysregulated serum response factor triggers formation of hepatocellular carcinoma
Stefan Ohrnberger, Abhishek Thavamani, Albert Braeuning, Daniel B. Lipka, Milen Kirilov, Robert Geffers, Stella E. Authenrieth, Michael Römer, Andreas Zell, Michael Bonin, Michael Schwarz, Günther Schütz, Peter Schirmacher, Christoph Plass, Thomas Longerich, Alfred Nordheim – 29 September 2014 – The ubiquitously expressed transcriptional regulator serum response factor (SRF) is controlled by both Ras/MAPK (mitogen‐activated protein kinase) and Rho/actin signaling pathways, which are frequently activated in hepatocellular carcinoma (HCC).
Differences in long‐term survival among liver transplant recipients and the general population: A population‐based nordic study
Fredrik Åberg, Mika Gissler, Tom H. Karlsen, Bo‐Göran Ericzon, Aksel Foss, Allan Rasmussen, William Bennet, Michael Olausson, Pål‐Dag Line, Arno Nordin, Annika Bergquist, Kirsten Muri Boberg, Maria Castedal, Christian Ross Pedersen, Helena Isoniemi – 29 September 2014 – Dramatic improvement in first‐year outcomes post‐liver transplantation (LT) has shifted attention to long‐term survival, where efforts are now needed to achieve improvement. Understanding the causes of premature death is a prerequisite for improving long‐term outcome.